From: Suicidal ideation and behavior among subjects with substance abuse disorder related to pregabalin
Variable | (n = 83) | ||
---|---|---|---|
No | % | ||
Cannabis (smoking) | Yes | 54 | 65.1 |
Dose (cig) | Median (IQR) | 5(4–10) | |
Duration (years) | Median (IQR) | 9.5(5–14) | |
Tramadol (oral) | Yes | 56 | 67.4 |
Dose (mg) | Median (IQR) | 950(232.25–2250) | |
Duration (years) | Median (IQR) | 7(4–11) | |
Heroin | Yes | 55 | 66.3 |
Route | Sniff | 23 | 41.8 |
Dose (gm.) | IV | 32 | 58.2 |
Duration (years) | Median (IQR) | 3(2–5) | |
Median (IQR) | 4(2–9) | ||
Benzo (oral) | Yes | 23 | 27.7 |
Dose (mg) | Median (IQR) | 8(4–20) | |
Duration (years) | Median (IQR) | 5(3–10) | |
Other | Yes | 37 | 44.6 |
Type | Conventin (oral) | 18 | 21.7 |
Gabamash (oral) | 4 | 4.8 | |
Gabtin (oral) | 1 | 1.2 | |
Gak 300 mg (oral) | 1 | 1.2 | |
Parkinol (oral) | 1 | 1.2 | |
Powder (Sniff) | 1 | 1.2 | |
Rometril (IV) | 1 | 1.2 | |
Shadow (Sniff) | 1 | 1.2 | |
Snapgab (oral) | 1 | 1.2 | |
Strox (Sniff) | 4 | 4.8 | |
Tusskan (oral) | 4 | 4.8 | |
Duration (duration) | Median (IQR) | 6 months (5 months–1 year) | |
Urine test | −ve | 31 | 37.3 |
+ve | 52 | 62.7 | |
Opioid | 34 | 41 | |
Benzo | 7 | 8.4 | |
Cannabis | 29 | 34.9 | |
Tramadol | 12 | 14.5 |